Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Japan Generic Market Projected at 1.2 Trillion Yen in 2021: Fuji Keizai
April 6, 2018
- Takeda, DNDi to Collaborate in Visceral Leishmaniasis Drug Development
April 6, 2018
- Daiichi Sankyo Expands Cancer Collaboration with DarwinHealth
April 6, 2018
- Takeda to Divest Its Brazilian OTC, Gx Subsidiary to Local Pharma
April 6, 2018
- Zyprexa Generics Now Carry Same Indications as Originator
April 5, 2018
- Nebulized COPD Med Lonhala Magnair Now Available in US: Sunovion
April 5, 2018
- Nichi-Iko to Raise 21.2 Billion Yen for Elmed Eisai Buyout
April 5, 2018
- Nihon Medi-Physics’ Project to Develop Labeled Antibody Therapeutics Selected for AMED’s CiCLE Grant Program
April 4, 2018
- Mochida Targets Sales of 103 Billion Yen in FY2020, Adding Gastroenterology to Priority Fields: New Biz Plan
April 4, 2018
- Fycompa Filed for Label Expansion in US for Pediatric Epilepsy
April 3, 2018
- Sanofi Seeks Asthma Indication for Dupixent in Japan
April 3, 2018
- Kyorin Nabs Rights to Sanwa Kagaku’s Nocturia Drug in Japan, Asia
April 3, 2018
- Apomorphine Sublingual Film Filed in US: Sunovion
April 3, 2018
- Daiichi Sankyo Alters Terms of Settlement over US Olmesartan Products Liability Litigation
April 3, 2018
- Ambicion Obtains Global Rights to RIKEN’s NKT Cell-Targeted Anti-Cancer Therapy
April 3, 2018
- Shionogi Trio Puts Up Add’l 1.8 Billion Yen Each for Peptide Therapeutics JV
April 2, 2018
- Zeria Files Iron Deficiency Med in Japan
April 2, 2018
- Nippon Kayaku Notches Top Court Victory for Elplat Damages Suit Too
April 2, 2018
- Kihito Takahashi Tapped as EVP of GSK Japan
April 2, 2018
- Lynparza Companion Diagnostic Approved in Japan: AZ
April 2, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…